[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346395-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346395-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","artificial-intelligence-in-hematologic-malignancies-opportunities-challenges-and-clinical-integration","Artificial Intelligence in Hematologic Malignancies - Opportunities, Challenges, and Clinical Integration","","Artificial intelligence (AI) has shown significant potential for hematologic malignancies by improving diagnostic accuracy, enhancing prognostic models, and supporting personalized treatment decisions. AI systems have demonstrated strong performance in automated image classification, genomic and biomarker analysis, prediction of treatment response and toxicity, and estimation of measurable residual disease. Despite these advances, reviews highlight barriers such as limited dataset sizes, insufficient prospective validation, interpretability concerns, and ethical risks involving privacy and bias. Robust integration strategies and high-quality multi-team collaboration are emphasized.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/artificial-intelligence-in-hematologic-malignancies-opportunities-challenges-and-clinical-integration/346395/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/artificial-intelligence-in-hematologic-malignancies-opportunities-challenges-and-clinical-integration/346395.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does AI support diagnosis and prognosis in hematologic malignancies?","Question",{"text":63,"@type":64},"AI can enhance diagnostic accuracy and refine prognostic models. Reported capabilities include automated image classification and prediction of patient outcomes based on clinical, genomic, and biomarker data.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What challenges limit clinical use of AI tools in this field?",{"text":68,"@type":64},"Key challenges include limited dataset size, lack of prospective validation, concerns about interpretability, and ethical issues related to data privacy and bias.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review emphasize for successful clinical integration of AI?",{"text":72,"@type":64},"The review emphasizes robust clinical integration strategies, high-quality data, and collaboration across multiple teams to fully realize AI’s potential in transforming hematologic malignancy management.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346395,1791161407,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Review began 12/03/2025  \nReview ended 12/16/2025  \nPublished 01/06/2026  \n© Copyright 2026  \nSalem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited.  \nDOI: 10.7759/cureus.100950  \nOpen Access Review Article  \nArtificial Intelligence in Hematologic Malignancies: Opportunities, Challenges, and Clinical Integration  \nAya Salem 1, Mahmoud Teama 2, Hassan A. Kassem 3 , Niyousha Vakilzadehian 4, Arig Mahmoud Abdelaziz Ali 5, Dharaneswar Venugopal 6 , Ahmed M. Khalifa 7  \n1. Dermatology and Venerology, El Anfoushi Children Hospital, Alexandria, EGY 2. General Medicine, King’s College Hospital NHS Foundation Trust, London, GBR 3. Critical Care, King’s College London, London, GBR 4. General Internal Medicine, King’s College London, London, GBR 5. Gastroenterology and Hepatology, Cairo Fatemic Hospital, Cairo, EGY 6. Neuro Rehabilitation, King’s College Hospital NHS Foundation Trust, London, GBR 7. Cardiology, Frimley Park Hospital, Frimley Health NHS Foundation Trust, Frimley, GBR  \nCorresponding author: Aya Salem, [aya.salem33@gmail.com](aya.salem33@gmail.com)  \nAbstract  \nArtificial intelligence (AI) has shown significant potential in enhancing diagnostic accuracy, refining prognostic models, guiding personalized treatment decisions, and improving clinical workflows. Across the spectrum of blood cancers, AI-based tools have demonstrated strong performance in tasks such as automated image classification, genomic and biomarker analysis, prediction of treatment response and toxicity, and estimation of measurable residual disease. Despite these promising developments, challenges remain, including limited dataset size, lack of prospective validation, concerns regarding interpretability, and ethical considerations related to data privacy and bias. The review emphasizes the need for robust clinical integration strategies, high-quality data, and multiple teams ' collaboration to fully harness AI’s potential in transforming the management of hematologic malignancies.  \nCategories: Hematology  \nKeywords: artificial intelligence, deep learning, hematologic malignancies, leukemia, lymphoma, machine learning, multiple myeloma, personalized medicine, prognosis, radiomics  \nIntroduction And Background  \nHematologic malignancies comprise a diverse group of cancers that originate from cells within the bloodforming system, including leukemia, lymphoma, and myeloma [1] . These conditions present clinically with signs of insufficient or suppressed bone marrow function, including a propensity for bleeding, susceptibility to infections, and anemia [2,3] .  \nThe rapid advancement of computer science over the last decade has led to the widespread integration of artificial intelligence (AI) as a standard feature across various sectors, most notably within healthcare [4] . AI is a computer program that enables machines to simulate certain human thought processes and intelligent behaviors, helping to solve complex problems. Machine learning (ML), a subset of AI, is a valuable supportive tool that seeks out comparable patterns within datasets. These capabilities enable the creation of various models for accomplishing complex tasks. Exciting areas of development in AI include natural language processing (NLP), large language models (LLMs), explainable AI (XAI), and generative AI. While these are all interconnected, each branch or technology possesses distinct characteristics and fields of application [5] .  \nML tools show great promise across many medical disciplines [6-9], particularly in oncology. Various algorithms have been suggested for applications like assessing cancer risk, automating segmentation, identifying and characterizing lesions, determining grading and staging, and predicting patient outcomesand treatment effectiveness [10]. This study aims","cbCaih8XKdRPYi5l","https://ap.wps.com/l/cbCaih8XKdRPYi5l","pdf",486365,"English","# Introduction and Background\n# Review\n## The need for AI in hematologic malignancies\n## How to cite this article\n## AI applications in hematology","[{\"question\":\"How does AI support diagnosis and prognosis in hematologic malignancies?\",\"answer\":\"AI can enhance diagnostic accuracy and refine prognostic models. Reported capabilities include automated image classification and prediction of patient outcomes based on clinical, genomic, and biomarker data.\"},{\"question\":\"What challenges limit clinical use of AI tools in this field?\",\"answer\":\"Key challenges include limited dataset size, lack of prospective validation, concerns about interpretability, and ethical issues related to data privacy and bias.\"},{\"question\":\"What does the review emphasize for successful clinical integration of AI?\",\"answer\":\"The review emphasizes robust clinical integration strategies, high-quality data, and collaboration across multiple teams to fully realize AI’s potential in transforming hematologic malignancy management.\"}]","Artificial Intelligence in Hematologic Malignancies - Opportunities, Challenges, and Clinical Integration | PDF",1790061260,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6ec80ab738d5175f043592681bef167.webp",983,1390,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/447aa13a473a8bc693776be02c377789.webp",982,1389,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d27eb53dbc5d8fc2bb965849e748c764.webp",981,1387,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a265e2c84e39b6bdbf436544fdc8cf8.webp",980,1386]